logo

Durect Corp. (DRRX)



Trade DRRX now with
  Date
  Headline
11/12/2019 8:50:47 AM DURECT Announces Positive Results From Phase 2a Trial Of DUR-928 In Alcoholic Hepatitis Patients
10/7/2019 8:03:53 AM DURECT Closes Enrollment In Phase2a Trial Of DUR-928 In Psoriasis And 50% Enrollment In Phase 1b DUR-928 Trial In NASH
10/2/2019 8:05:59 AM DURECT Reports FDA Advisory Committee Meeting To Review POSIMIR For Treatment Of Post-Surgical Pain
9/23/2019 5:50:04 AM What Awaits DURECT In Q4?
9/17/2019 8:01:51 AM DURECT Announces Positive Data From Its Phase 2a Clinical Trial Of DUR-928 In Alcoholic Hepatitis
7/22/2019 8:04:20 AM DURECT, Gilead Enter License Agreement For Long-Acting Injectable HIV Investigational Product
7/17/2019 8:06:24 AM DURECT Says FDA Agrees To File Full Response To POSIMIR Complete Response Letter
6/27/2019 8:37:16 AM DURECT Announces Submission To FDA Of Full Response To POSIMIR Complete Response Letter
6/20/2019 8:09:56 AM DURECT Announces $15 Mln Registered Direct Offering
6/18/2019 8:08:54 AM DURECT Completes Dosing 90 Mg Cohort Of Severe AH Patients In Ongoing DUR-928 Phase 2a Clinical Trial
3/27/2019 8:03:21 AM DURECT Announces Patient Enrollment In Phase 1b Clinical Trial Of Oral DUR-928 In Patients With NASH
3/21/2019 8:03:44 AM DURECT Begins Patient Dosing In Phase 2a Proof-of-concept Trial With Topical DUR-928
  
 
>